FoundationOne®Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw. It is the only FDA-approved blood-based test to analyze over 300 genes**—making it the most comprehensive FDA-approved liquid biopsy on the market. Plus, as a professional service, which has not been reviewed or approved by the FDA, this test reports blood tumor mutational burden (bTMB), microsatellite instability high (MSI-H), and tumor fraction values1.
With targeted therapy options, comprehensive genomic profiling with FoundationOne Liquid CDx can help guide treatment strategies and help predict patient benefit across multiple cancer indications. Foundation Medicine’s test portfolio enables you to easily reflex FoundationOne Liquid CDx, a blood-based test, to FoundationOne®CDx, a tissue-based test, or vice versa.‡
Coverage includes:
- National coverage for qualifying Medicare2 and Medicare Advantage3 across all solid tumors.4
- 80 commercial health plans cover one or more Foundation Medicine tests.
With such broad coverage, 87% -- or nearly 9 out of 10 patients -- pay $0 for testing.5